Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Biotech Startup Begins Operations in Takeda’s Shonan Research Center
August 2, 2017
- Bayer Yakuhin Finds 85 Further Cases of Unreported ADRs
August 2, 2017
- No Policy Change in Obtaining Regulatory Approval of Nesp Biosimilar through New Firm: Kyowa Kirin President
August 1, 2017
- August FDA Filing Planned for FGF23 Antibody Burosumab: Kyowa Kirin
July 31, 2017
- Abilify-Jzoloft Combo Filed in Japan: Otsuka
July 31, 2017
- Kyowa Kirin Enjoys Higher Earnings on Benralizumab License Revenue
July 31, 2017
- AZ Labor Tribunal with 3 Employees Falls Apart, Civil Suit to Begin
July 31, 2017
- Rohto to Commence Clinical Trial of Regenerative Medicine Product for Hepatic Cirrhosis
July 31, 2017
- Mitsubishi Tanabe Begins Japan PII/III for Dyskinesia Med
July 28, 2017
- Astellas to Move Away from ADCs, Shuts Agensys Research Operations
July 28, 2017
- 3 Generic Makers Ordered to Pay Damages over Oxarol Patent Infringement
July 28, 2017
- Takeda Gets Rights to Tesaro’s PARP Inhibitor in Japan, Other Markets
July 28, 2017
- Chugai Nets Half-Year Revenue Rise on Milestone Income
July 28, 2017
- Fycompa Approved for Monotherapy for Partial Epilepsy in US
July 28, 2017
- Takeda, BioSurfaces Hook Up on Devices for GI Diseases
July 27, 2017
- Fujifilm to Invest 500 Million Yen in Bonac; Will Engage in Joint Research to Discover Nucleic Acid Medicines
July 27, 2017
- Linzess Off to Solid Start, Astellas Eyes Big Indication Addition
July 26, 2017
- Lenvatinib Filed for HCC in US and EU after Japan Submission
July 26, 2017
- AZ Japan to Work to Create “Frameworks for Success”: Commercial Excellence Head
July 26, 2017
- Sumitomo Dainippon to Invest up to US$10 Million in Investment Partnership
July 26, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…